Pfizer Contests Lipitor Rule
By Robert Steyer
TheStreet.com Staff Reporter
3/29/2005 2:18 PM EST
Pfizer (PFE:NYSE - news - research) said Tuesday that it would appeal a decision by the Austrian Patent Office that invalidated a patent on the main ingredient in its cholesterol-fighting drug Lipitor.
Pfizer says the patent challenge, filed by the Indian generic drug company Ranbaxy Laboratories, doesn't affect litigation in other countries, including the U.S. Ranbaxy also is challenging the U.S. patent which expires in 2011.
Full story.
